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Aim: Insulin therapy is commonly associated with weight gain. The timing of prandial insulin administration may enhance its efﬁcacy/safety
and maintain effective weight control. This study examined the effect of postprandial vs. preprandial insulin glulisine on weight gain and
glycaemic control in type 2 diabetes patients taking basal insulin.
Methods: This was a multicenter, randomized, open-label trial conducted in 45 centres in the USA. A total of 716 patients with type 2 diabetes
a n dg l y c a t e dh a e m o g l o b i nA 1c (HbA1c) ≥7.5% and ≤10.0% were screened; 345 were randomized and 322 comprised the intent-to-treat group
(premeal, 163; postmeal, 159). Insulin glargine once daily, ±metformin and subcutaneous injections of premeal or postmeal insulin glulisine
were given for 52 weeks. Main outcome measures included changes in HbA1c, fasting plasma glucose and weight from study baseline to
endpoint (week 52).
Results: At study end, insulin glulisine achieved similar glycaemic control whether it was administered before or after meals (HbA1c: 7.04%
premeal vs. 7.16% postmeal, p = NS). Overall hypoglycaemia incidence and severe hypoglycaemia rates were not signiﬁcantly different
between premeal and postmeal groups; however, symptomatic and nocturnal hypoglycaemia rates were higher in the postprandial group.
Mean body weight was lower in the postmeal group, with the difference between postmeal and premeal weight change from baseline to
week 52 of −0.87 kg (p = 0.243).
Conclusion: Postprandial glulisine administration provided similar glycaemic control and was non-inferior to preprandial administration on
weight gain, without additional risk of severe hypoglycaemia, showing dosing ﬂexibility and the feasibility of such approach when clinically
indicated.
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Introduction
Theprevalence oftype 2diabetes continues toincrease,as does
the number of obese individuals in the USA, with 80 to 90%
of patients with type 2 diabetes being overweight or obese [1].
It is widely recognized in published literature [2–4], as well
as in consensus treatment guidelines [5], that insulin is highly
effective in reducing blood glucose (BG) and maintaining
glycaemic control. Type 2 diabetes is a progressive disease
characterized by ongoing loss of β-cell function leading to oral
agent failure and the need for insulin-replacement therapy.
Treatment with basal insulin generally provides effective
glycaemic control for most patients. Over time, however, the
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addition of prandial insulin to basal therapy is often required
for patients to minimize postprandial glucose excursions and
maintain glycaemic control. The combination of basal and
prandialinsulintherapycloselymimicsthenormalphysiologic
pattern of endogenous insulin release and improves glycaemic
control [3,6].Intensive,physiologicinsulinreplacementinthis
manner, however, has been associated with undesired weight
gain [7].
Recentyearshavewitnessedthedevelopmentofseveralnovel
antihyperglycaemic agents, as well as advances in the delivery
and pharmacology of insulin therapy to help patients meet
their glycaemic goals [8]. The currently available options for
prandial insulin therapy include regular human insulin (RHI)
and rapid-acting insulin (RAI) analogues. RAIs have several
advantagesoverRHI,includingatime-actionproﬁlethatmore
closely mimics endogenous insulin, the capability of injectionDIABETES, OBESITY AND METABOLISM original article
within15 minofamealcomparedwith30–45minrequiredfor
RHI,andbettercontrolofpostprandialglucoseexcursions [9].
Because of changing lifestyles, including variable meal times,
adherence to the 30-min injection-premeal lag time typically
recommended for RHI can be difﬁcult for many patients [10].
Therefore, it is important to identify treatments that can help
patients achieve their glycaemic goals while providing effective
ﬂexible insulin dosing options.
InsulinglulisineisanRAIanaloguethatdisplaysamorerapid
onset, an earlier peak effect, and a shorter duration of action
than RHI [3,11], with uniform absorption and efﬁcacy among
wide ranges of body mass indexes (BMIs) [12]. The time-
action proﬁle of insulin glulisine may provide the advantage of
adjusting doses according to actual food intake, as this insulin
is also indicated for use within 20 min after the start of a
meal [13]. Dose adjustment, in turn, may allow patients to
decrease the meal size, thereby enhancing the effect of insulin
in improving glycaemic control and modulating body weight.
Postmealadministrationofinsulinglulisinehasbeenstudied
in patients with type 1 diabetes, and was shown to provide
glycaemic control equivalent to that of premeal insulin
glulisine and RHI, with a small but statistically signiﬁcant
body weight loss over 12 weeks [6]. In addition, no differences
in symptomatic or nocturnal hypoglycaemia rates were shown
between groups [6]. These results have not yet been conﬁrmed
in patients with type 2 diabetes.
This study was undertaken to assess whether postprandial
useofinsulinglulisinewouldbenon-inferiortopreprandialuse
inglycaemiccontrolwithparticularattentiontoweightchanges
in patients with type 2 diabetes suboptimally controlled with
oral antihyperglycaemic agents and insulin.
Methods
Patients
Three hundred and forty-ﬁve patients were recruited from
45 centres in the USA. Patients were male and female, aged
18–70 years, with a diagnosis of type 2 diabetes for at least
6 months, and with inadequately controlled diabetes (HbA1c
≥7.5% and ≤10.0% at screening) on current therapy. Patients
were required to have been on insulin therapy with at least two
injections per day ±metformin for a minimum of 3 months
prior to the study entry. All participants showed the ability
and willingness to perform self-monitoring of blood glucose
(SMBG) at least four times per day and at least seven times
daily during the seven-point BG proﬁle measurement days.
Patients were excluded from this study if they were treated
with sulfonylureas, thiazolidinediones, or any other oral
antidiabetic drugs other than metformin within 3 months
prior to the study entry; were treated with metformin and
had serum creatinine levels of ≥132.6 μmol/l (male patients)
or ≥123.8 μmol/l (female patients); or hepatic disease; had
serum alanine aminotransferase or aspartate aminotransferase
levels >2.5 times the upper limit of normal.
Study Design
This was a multicenter, controlled, open-label, 1 : 1, random-
ized, parallel-group study consisting of a 2-week screening
period and a 52-week treatment period. During screening,
qualiﬁed patients remained on their pre-existing insulin reg-
imen and received dietary and lifestyle recommendations
from a health care professional. Patients then were random-
ized to: (i) premeal arm—patients received insulin glulisine
three times daily, 0–15 min before the three main meals,
and insulin glargine once daily, ±metformin or (ii) postmeal
arm—patients received insulin glulisine three times daily,
20 min afterthe startofa meal, and insulin glargine oncedaily,
±metformin.
Treatments
All patients received a single daily subcutaneous (SC) injection
of insulin glargine, the initial dose being 50% of the total daily
insulin dose from the patient’s previous treatment. The timing
of insulin glargine administration was based on the needs of
individual patients. A change in timing was permitted during
the ﬁrst 6 months after randomization if deemed appropriate
by the investigator; however, the change could be made only
once per patient. Weekly dose titration was based on the mean
of the fasting 3-day SMBG values to achieve a fasting plasma
glucose (FPG) level of <6.1 mmol/l (110 mg/dl) and an HbA1c
level of <7.0% (Table 1). The dose increase could be split into
two ormore incremental increases over the course ofthe week.
Insulin glulisine was administered SC, either 0–15 min
before each main meal or 20 min after the start of a meal
in accordance with product labelling. The initial dose of
insulin glulisine in both arms was 50% of the total daily
insulin dose from the patient’s previous treatment. The total
bolus insulin was divided to provide appropriate mealtime
coverage; three sixths of the daily bolus dose was given with
the largest meal (∼50%), two sixths—with the second largest
meal(∼33%),andonesixth—withthesmallestmeal(∼17%).
Patients randomized to the postmeal arm received insulin
glulisine 20 min after the start of each meal, and the dose was
adjusted based on the actual food intake during that speciﬁc
meal. For example, if a full planned meal was consumed, 100%
of the planned dose was taken; if half of the planned meal
was consumed, 50% of the planned dose was taken; and if
one fourth of the planned meal was consumed, 25% of the
Table 1. Insulin glargine titration algorithm.
HbA1c
Mean fasting
3-day SMBG
(mmol/l)
Insulin glargine
adjustment (U)
≥7.0% >10.0 Increase 8 U
7.8–10.0 Increase 6 U
6.7–7.7 Increase 4 U
6.1–6.6 Increase 2 U
5.6–6.0 Increase 0–2 U at investigator’s discretion∗
3.9–5.5 No change
<3.9 Decrease the dose of insulin glargine by 10%
<7.0% <3.9 Decrease the dose of insulin glargine by 10%
HbA1c, glycated hemoglobin A1c; SMBG, self-monitored blood glucose.
∗If the HbA1c was ≥7.0% and the mean FPG was between 5.6 and
6.0 mmol/l (100 and 109 mg/dl), the investigator decided if the patient
should receive a dose increase or not.
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Table 2. Insulin glulisine titration algorithm.
Mealtime dose
Pattern of low
preprandial blood
glucose values∗
Pattern of high
preprandial blood
glucose values†
≤10 U Decrease by 1 U Increase by 1 U
1 1–1 9U D e c r e a s eb y2U I n c r e a s eb y2U
≥20 U Decrease by 3 U Increase by 3 U
∗Two or more values of <3.9 mmol/l (70 mg/dl).
†Four or more values of ≥6.1 mmol/l (110 mg/dl) or 4 or more values of
≥7.2 mmol/l (130 mg/dl) at bedtime.
planned dose was taken. Weekly dose titration for adjusting
premeal and postmeal insulin glulisine was based on a pattern
managementapproachofpreprandialSMBGvaluespreviously
described by Bergenstal and coworkers [14]. Brieﬂy, insulin
glulisine dose adjustment for both treatment groups was based
on speciﬁc patterns of prelunch, predinner and prebedtime
(collectively referred to as mealtime) prandial BG levels, with
targets for preprandial (before lunch and dinner) BG of
<6.1 mmol/l (110 mg/dl) and bedtime BG of <7.2 mmol/l
(130 mg/dl, Table 2). Patients receiving metformin at the
time of randomization continued receiving the same dose
throughout the entire treatment phase.
Study Outcomes
The primary efﬁcacy objective was to compare weight change
from baseline to week 52 in patients receiving postmeal vs.
premeal insulin glulisine with insulin glargine as basal insulin.
Additional efﬁcacy assessments included a comparison of total
insulin dose; change in weight from baseline to weeks 3, 6,
12, 20, 28, 36, 44 and 52; proportion of patients experiencing
>5% and >10% change in body weight; HbA1c measurements
at weeks 0, 12, 28, 36 and 52, or at study discontinuation
between patients receiving insulin glulisine before meals and
aftermeals;andproportionofpatientsachievingHbA1c <7.0%
and <6.5%. Safety endpoints included the incidence and rate
of hypoglycaemic events, based on severity, recorded by each
patient in the patient diary.
Statistical Analysis
Data analyses were conducted based on three speciﬁed
populations. The per-protocol (PP) population (the main
population for the non-inferiority testing of the primary
endpoint) included all randomized patients who took study
medication, had no major protocol violations, and had
body weight recorded at baseline and week 52. The intent-
to-treat (ITT) population consisted of randomized patients
with baseline measurements and at least one postbaseline
measurement of weight and HbA1c taken after randomization
and was the main population for the superiority testing of the
secondary endpoints. This population excluded subjects from
1 study site for Good Clinical Practice non-compliance. The
safety analysis population consisted of all patients who took at
least one dose of study medication.
Comparison of treatment effect on body weight change
was based on a non-inferiority hypothesis with an upper
bound from a two-tailed 95% conﬁdence interval (CI) on the
difference of the mean weight change of ≤1.5 kg between the
two treatment arms. At each study site, the same scale was
used at every visit for weight, without coats, sweaters, shoes,
and with empty pockets. The non-inferiority in the change
from baseline to week 52 in weight was investigated using
analysis of covariance (ANCOVA; PROC MIXED in SAS). The
model included change from baseline as a dependent variable;
treatment,pooledsite,andrandomizationstrata(includingthe
number ofdailyinjectionspriortothe study,use ofmetformin
at randomization, and injection methodology) as ﬁxed effects;
and baseline weight as a covariate.
The change from baseline to study time points in weight,
HbA1c, FPG, dose of insulin glargine, dose of insulin
glulisine, and total insulin dose were analysed using repeated
measurement ANCOVA based on the ITT population. The
geometric means for concentration data were calculated from
the least squares means of logs for each treatment. The p
values were based on the test of log ratios. The proportions
of patients with weight increases of >5% or >10% baseline
body weight and proportions achieving HbA1c targets <7.0%
and <6.5% were determined. Odds ratio (OR) estimates, 95%
CI, and p values were established with logistic regression
models including treatment arm, injection method, number of
injections, metformin use, and baseline weight or HbA1c.T h e
safety population was used for the analysis of hypoglycaemic
event rates. The logistic regression model was used to assess
the difference, if any, between the two treatment arms for
symptomatic,severe,nocturnal,orserioushypoglycaemia.The
analysisincludedthe95%CIsofORsandpvalues.Thenumber
of episodes per patient-year was estimated for each event of
hypoglycaemia by using the log-rank or Poisson regression
model.
A trial with sample size of 105 evaluable subjects per
treatment has 80% power to detect a treatment difference
in body weight change of 1.5 kg in a superiority trial. With
105 evaluable subjects per arm, a non-inferiority hypothesis
test with an equivalence limit of 1.5 kg also has 80% power.
The standard deviation used in the power computations was
σ = 3.83. This is the 95% upper conﬁdence limit of the
standard deviation of weight change from a previous insulin
glulisine clinical trial.
Results
Patients
A total of 716 patients were screened for randomization; 371
patients did not meet criteria for study inclusion and 345
patients were randomized on a 1 : 1 basis to the premeal or
postmeal insulin glulisine group. One randomized patient in
thepostmealarmwithdrewfromthestudybeforereceivingthe
ﬁrstdoseofstudymedicationandwasthereforenotincludedin
the safety population. Thus, the safety population comprised
173 patients in the premeal group and 171 in the postmeal
group. Overall, 229 patients (66%) completed the study; 32%
of patients in the premeal group and 36% in the postmeal
group discontinued the study for reasons including ‘did not
wish to continue’ (16 and 17% of patients in the two groups,
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Table 3. Patient baseline characteristics and demographics, safety
population.
Premeal
(n = 173)
Postmeal
(n = 171)
Age, year (mean ± SD) 53.9 ± 9.25 3 .7 ± 9.9
Female, n (%) 98 (56.6) 96 (56.1)
Race, n (%)
White 129 (74.6) 125 (73.1)
Black 26 (15.0) 26 (15.2)
Asian 7 (4.0) 3 (1.8)
Multiracial 4 (2.3) 3 (1.8)
Other 7 (4.0) 14 (8.2)
Age at onset, year (mean ± SD) 41.2 ± 10.44 0 .9 ± 9.7
Diabetes duration, year (mean ± SD) 13.9 ± 7.61 4 .0 ± 6.9
Baseline HbA1c,%( m e a n± SD) 8.4 ± 0.78 8.3 ± 0.75
Weight, kg (mean ± SD) 106.5 ± 24.1 105.4 ± 21.4
BMI, kg/m2(mean ± SD) 37.4 ± 8.03 7 .0 ± 7.8
FPG, mmol/l (mean ± SD) 9.6 ± 3.69 .5 ± 3.7
mg/dl (mean ± SD) 173 ± 65 170 ± 67
Number of injections, n (%)
Two per day 42 (24.3) 47 (27.5)
More than two per day 131 (75.7) 124 (72.5)
BMI, body mass index; FPG, fasting plasma glucose; HbA1c,g l y c a t e d
haemoglobin A1c.
respectively), lost to follow-up (3.5 and 5.8%, respectively),
adverse events (2.9, 4.1%), protocol violation (2.9, 1.2%), lack
of efﬁcacy [1 patient (0.6%) in the premeal group], death [2
patients (1.2%) in the premeal group], and other (4.6, 7.6%).
Patient demographics and baseline characteristics were
similar for the two study arms (Table 3). Excluding the site
with Good Clinical Practice non-compliance, the ITT set
comprised 322 patients, with 163 patients in the premeal
and 159 in the postmeal group. On average, the ITT group
had a mean age of 54 years, approximately 56% were female,
and BMI was 37 kg/m2. For the premeal and postmeal groups
(ITT) baseline weight was 107 and 106 kg, HbA1c level was
8.4 and 8.3%, and FPG level was 9.7 and 9.3 mmol/l (174 and
168 mg/dl), respectively. The PP population included 107 in
the premeal group and 106 in the postmeal administration
group. The mean body weight in the PP population at
baseline was 106.5 kg (premeal) and 108.2 kg (postmeal).
Demographics and background information were similar in
all three populations studied.
Weight Change from Baseline to Study End
Non-inferiority of weight change from baseline at the week
52 visit was shown. Adjusted means (SE) were 5.53 (0.61) kg
and 4.66 (0.61) kg for the premeal and postmeal PP groups,
respectively, and the upper 95% conﬁdence bounds on
the difference in mean weight change between the two
treatmentarmswerewithinthenon-inferioritymarginof1.5kg
speciﬁedinthestudyprotocol[week52:postmeal—premeal =
−0.87 kg with 95% CI (–2.35 to 0.60)]. The difference in
body weight change was not signiﬁcant (p = NS). Similarly,
when this comparison was repeated in the ITT population, the
adjustedmean(SE)weightgainatstudyendwas5.42(0.59)and
4.69(0.60) kg(p = NS)inthepremealandpostmealtreatment
groups,respectively[week52:postmeal—premeal =− 0.73 kg
with 95% CI (–2.17 to 0.71)]. The secondary, repeated
measures analysis in the ITT population showed the mean
weight gain across the 52 week time period (to weeks 3, 6,
12, 20, 28, 36, 44 and 52) was consistently numerically lower
in the postmeal than in the premeal arm, although these
differences were not signiﬁcant at any time point (Figure 1)
[week 52: postmeal—premeal =− 1.1 kg with 95% CI (−2.28
to 0.13)]. Weight change across the 52-week time period was
alsoexaminedforthePPpopulation,withsimilarresults[week
52: postmeal—premeal =− 0.96 kg with 95% CI (−2.26 to
0.34)]. The proportion of patients with a weight increase of
>5% or >10% of their body weight from baseline to endpoint
did not reach statistical signiﬁcance for premeal vs. postmeal
administration [>5%: 45% of patients in the premeal group
and 36% of patients in the postmeal group, OR (95% CI) =
0.68 (0.43, 1.06), p = 0.085; >10% : 14% and 10% of patients,
OR (95% CI) = 0.71 (0.36, 1.14), p = 0.334; respectively].
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Figure 1. Adjusted mean (SE) change in premeal and postmeal weight from baseline to study endpoint (week 52) following insulin glulisine treatment
across study weeks (visit weeks 0, 3, 6, 12, 20, 28, 36, 44 and 52). ITT, intent to treat.
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Figure 2. Effect of premeal and postmeal insulin glulisine treatment on HbA1c levels. Panel A shows the change in mean (SD) HbA1c across study weeks
(visit weeks 0, 12, 28, 36 and 52). Panel B shows the seven-point blood glucose proﬁles for both treatment groups (showing mean (SD) values at each time
point at baseline and at week 52). HbA1c, glycated hemoglobin A1c. ITT, intent to treat.
Insulin Dose
The adjusted mean titrated doses for insulins glulisine and
glargine increased in both treatment arms over the course of
thestudy withno difference (p ≥ 0.5) between treatmentarms
in insulin glulisine or glargine requirement. Patients in the
premeal and postmeal arms achieved an adjusted mean total
insulin dose of 2.37 and 2.23 U/kg, respectively, at study end
(p = NS; ITT).
Glycaemic Control
At study end, patients treated with basal insulin glargine
plus premeal or postmeal insulin glulisine achieved similar
reductions in adjusted mean FPG levels of 6.6 mmol/l
(119 mg/dl) or 6.7 mmol/l (120 mg/dl), respectively. This
representsareductionof2.1 mmol/l(38 mg/dl)forthepremeal
group and 2.0 mmol/l (37 mg/dl) for the postmeal group from
baseline to endpoint (p = NS).
After28 weeks, patients in the premeal and postmeal insulin
glulisine group achieved similarreductions in HbA1c (6.86 and
6.96%,respectively; p = NS). At week 52, patients treated with
insulin glargine plus glulisine in the premeal arm achieved
an HbA1c level of 7.04 and 7.16% in postmeal arm. This
represents a reduction of 1.28% for the premeal and 1.15% for
the postmeal arm from baseline to endpoint (p = NS). HbA1c
measurementswerecomparableatvisitweeks12,28,36and52
for the two groups (Figure 2A). In addition, at study end, the
percentages of patients with HbA1c levels <7.0% and <6.5%
were also not signiﬁcantly different between treatment groups
[<7.0%: 36% of patients in the premeal group and 33% of
patients in the postmeal group, OR (95% CI) = 0.78 (0.49,
1.25), p = 0.305; <6.5%: 19 and 15% of patients, OR (95%
CI) = 0.64 (0.35, 1.17), p = 0.147; respectively].
Changes in preprandial and postprandial BG levels from
baseline at week 52 were captured by the seven-point BG
proﬁle, with a comparable decline in BG values observed in
both treatment groups (Figure 2B).
Hypoglycaemia
The incidence and rate of hypoglycaemic events were derived
from the safety population (Table 4). The premeal treatment
grouphad128severeepisodesin36patients(20.8%)compared
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Table 4. Incidence and rate of hypoglycaemic events.
Incidence Premeal (n = 173) Postmeal (n = 171) p value
<3.9 mmol/l and symptomatic 146 (84.4) 143 (83.6) 0.8539
<3.9 mmol/l and nocturnal 113 (65.3) 119 (69.6) 0.3952
<2.8 mmol/l and symptomatic 104 (60.1) 106 (62.0) 0.8901
<2.8 mmol/l and nocturnal 54 (31.2) 66 (38.6) 0.1653
Severe hypoglycaemia and serious hypoglycaemia 36 (20.8) 30 (17.5) 0.4369
Events per patient-year ± SE Premeal (n = 173) Postmeal (n = 171) p value
<3.9 mmol/l and symptomatic 29.0 ± 2.81 37.0 ± 3.55 0.05
<3.9 mmol/l and nocturnal 4.5 ± 0.60 7.7 ± 0.90 0.0017
<2.8 mmol/l and symptomatic 5.8 ± 0.85 7.5 ± 1.11 0.19
<2.8 mmol/l and nocturnal 1.1 ± 0.23 2.1 ± 0.42 0.01
Severe hypoglycaemia and serious hypoglycaemia 0.89 ± 0.23 0.5 ± 0.21 0.29
Severehypoglycaemia was deﬁned as an eventnecessitating the assistance of anotherparty with either a recordedSMBG levelof <2.0 mmol/l (<36mg/dl)
or an event requiring prompt response to treatment with oral carbohydrates, intravenous glucose or glucagon. A hypoglycaemic event was considered a
serious adverse event if it was associated with coma/loss of consciousness or hypoglycaemia seizure/convulsion.
with 73 episodes in 30 patients (17.5%) in the postmeal group.
Similarly, more patients in the premeal group (n = 8; 4.6%)
experiencedserioushypoglycaemiawith12episodescompared
with patients in the postmeal group (n = 3; 1.8%), who
experienced 5 episodes. There was no signiﬁcant difference
in the rate of severe and serious hypoglycaemia between
the premeal and postmeal treatment arms (0.89 vs. 0.54
events per patient-year; p = NS). However, compared with
the postmeal cohort, patients in the premeal treatment arm
experienced signiﬁcantly lower rates of low [<2.8 mmol/l
(<50 mg/dl)]andnocturnal(1.1 vs.2.1eventsperpatient-year;
p = 0.01) hypoglycaemic events, moderate and symptomatic
[<3.9 mmol/l (<70 mg/dl); 29.0 vs. 37.0 events per patient-
year; p = 0.05] hypoglycaemic events, and moderate and
nocturnal (<3.9 mmol/l (<7 0m g / d l ) ;4 . 5v s .7 . 7e v e n t sp e r
patient-year; p = 0.0017] hypoglycaemic events (Table 4).
Discussion
This randomized controlled study investigated the effect of
postmeal insulin glulisine administration on weight gain
and glycaemic control in patients with type 2 diabetes. The
postprandial administration showed consistently less weight
gain than preprandial administration throughout the 1-year
study; however, this did not reach statistical signiﬁcance at any
time point. Fewer patients using postprandial administration
compared with preprandial administration experienced a
>5% increase in total body weight (trend). Effective
glycaemic control with each respective basal-bolus regimen
was maintained for the 12 month duration of the study in
both groups. Both treatment groups achieved comparable
reductions from baseline in HbA1c level, with adjusted
mean HbA1c approaching 7.0% after 12 weeks of treatment.
Hypoglycaemia incidence was similar between premeal and
postmeal administration regimens, as was event rate of severe
hypoglycaemia; however, the postmeal group had higher rates
of low-to-moderate hypoglycaemic events, which reached
statistical signiﬁcance.
The pattern of overall weight change in this study is
consistent with that seen in an earlier randomized controlled
trial conducted by Bergenstal and colleagues that evaluated the
effectiveness of using a simple algorithm to adjust mealtime
insulin glulisine doses by weekly SMBG patterns vs. using
insulin-to-carbohydrateratios [14].Overatreatmentperiodof
24weeks,patientsutilizingthecarbohydratecountingapproach
toadjustmealtimeinsulinglulisineexperiencedlessweightgain
comparedwiththoseusingthesimplealgorithm(2.4 vs.3.6 kg;
p = 0.06 between-group difference at week 24). Common to
bothstudies,thelowerweightgainassociatedwithpostprandial
insulinglulisinedosingorcarbohydratecountingmaylikelybe
because of a relatively precise matching of prandial insulin to
the actual food consumed, rather than needing to eat sufﬁcient
quantities to match insulin doses administered before a meal.
Taken together, the current results and those of Garg and
colleaguessuggestthat,inpatientswithtype1ortype2diabetes,
the use of insulin glulisine after the meal with dosing based
on actual food consumption, may enable relatively precise
matching of mealtime insulin needs, particularly for patients
for whom food intake is difﬁcult to anticipate and adjustment
of meal size to insulin dose may not always be feasible.
Although preprandial dosing of RAI is considered to be
the standard practice, postprandial administration of insulin
glulisine has also been advocated by Mitri and colleagues [15],
focusing on the potential beneﬁt of postmeal administration
of short-acting insulins for the weight management of type 2
diabetes. In addition, postprandial RAI dosing has already
been successfully applied in a clinical practice model of
intervention [16].
A limitation of the current study was that quality of life and
treatmentsatisfactionmeasureswerenotobtained.Preprandial
RAI administration requires adjusting the meal size to the
insulin dose, whereas postprandial RAI administration allows
adjustment of the dose to the actual meal consumed. Lack
of dietary freedom has been shown to have a strong negative
effect on quality of life [17], therefore, regimens that provide
moreﬂexibilitymayimprovequalityoflife.Anotherlimitation
of this study is that no information was available pertaining
to compliance of medication administration timing. As in
usual practice, it is likely that some patients may not have
rigorously followed the exact timing of insulin administration
Volume 13 No. 12 December 2011 doi:10.1111/j.1463-1326.2011.01478.x 1147original article DIABETES, OBESITY AND METABOLISM
in relation to meals. However, this would have been the
same for both groups, so it would not affect study outcomes.
Future studies may want to explore the effects of the timing
of insulin administration on quality of life and treatment
satisfaction. Furthermore, generalizability to non-Caucasian
populations may be limited, as this study population included
a predominance of white patients and very few Asians, for
example, as β-cell function and dietary patterns may differ
between these patient groups.
Strengths of the current study include the use of both
PP and ITT statistical analyses for non-inferiority tests. This
providedtheopportunitytoassessweightchangeinboththose
with baseline and ≥1 post baseline assessment of weight at
any time point with last observation carried forward (ITT
analysis), and in a subpopulation of patients who had weight
measurementsatbaselineandweek52(PPanalysis).Theresults
were consistent across both statistical analyses populations,
showingnon-inferiorityofweightchangewiththepostprandial
and preprandial RAI dosing regimens.
Conclusion
This study shows the effectiveness and dosing ﬂexibility of
adding postprandial insulin glulisine to basal insulin glargine
aswellasoverallfeasibilityofsuchapproachinthemanagement
of type 2 diabetes when clinically indicated.
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